|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss | |||||
| Depreciation and amortization | |||||
| Original issue discount, debt premium and debt issuance cost amortization | |||||
| Debt modification and extinguishment costs (gain), net | |||||
| Interest paid on BR Exar Facility | |||||
| Debt modification and extinguishment gain, net | |||||
| Impairment of goodwill and other intangible assets | |||||
| Provision for doubtful accounts | |||||
| Impairment of operating lease right-of-use assets | |||||
| Credit loss expense | |||||
| Deferred income tax provision | |||||
| Share-based compensation expense | |||||
| Unrealized foreign currency gain | |||||
| (Gain) loss on sale of assets | |||||
| Fair value adjustment for interest rate swap | |||||
| Fair value adjustment for private warrants liability of XBP Europe | |||||
| Change in operating assets and liabilities | |||||
| Accounts receivable | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable and accrued liabilities | |||||
| Related party payables | |||||
| Additions to outsource contract costs | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities | |||||
| Purchase of property, plant and equipment | |||||
| Additions to patents | |||||
| Additions to internally developed software | |||||
| Proceeds from sale of assets | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance of Common Stock | |||||
| Private Placement | |||||
| At the Market Offering | |||||
| Subscription Agreements | |||||
| Cash received in exchange for the issuance of noncontrolling interest shares in XBP Europe | |||||
| Cash paid for equity issuance costs from at the market offerings | |||||
| Dividend paid on Series B Preferred Stock | |||||
| Payment for fractional shares on reverse stock split | |||||
| Repurchases of Common Stock for retirement | |||||
| Borrowings under factoring arrangement and Securitization Facility | |||||
| Principal repayment on borrowings under factoring arrangement and Securitization Facility | |||||
| Cash paid for withholding taxes on vested RSUs | |||||
| Lease terminations | |||||
| Cash paid for debt issuance costs | |||||
| Principal payments on finance lease obligations | |||||
| Borrowings under revolving facility | |||||
| BR EXAR | |||||
| Revolving Credit Facility BRCC Term Loan | |||||
| Total borrowings under revolving facility | |||||
| Repayments under revolving facility | |||||
| BR EXAR | |||||
| Total repayments under revolving facility | |||||
| Proceeds from issuance of July 2026 Notes | |||||
| Repayments on senior secured term loan and 2023 Notes as part of debts exchanges | |||||
| Borrowings from other loans | |||||
| Cash paid for debt repurchases | |||||
| Proceeds from Senior secured term loan | |||||
| Proceeds from Second Lien Note | |||||
| Repayment of BRCC term loan | |||||
| Principal repayments on senior secured term loans and other loans | |||||
| Net cash provided by (used in) financing activities | |||||
| Effect of exchange rates on cash, restricted cash and cash equivalents | |||||
| Net increase (decrease) in cash, restricted cash and cash equivalents | |||||
| Cash, restricted cash, and cash equivalents | |||||
| Beginning of period | |||||
| End of period | |||||
| Supplemental cash flow data: | |||||
| Income tax payments, net of refunds received | |||||
| Interest paid | |||||
| Noncash investing and financing activities: | |||||
| Assets acquired through right-of-use arrangements | |||||
| Leasehold improvements funded by lessor | |||||
| Issuance of April 2026 Notes in exchange of July 2026 Notes | |||||
| Issuance of April 2026 Notes in exchange of 2023 term loan | |||||
| Accrued PIK interest paid through issuance of PIK Notes | |||||
| Common Stock exchanged for Series B Preferred Stock | |||||
| Accrued liability for true-up obligation settled through the issuance of July 2026 Notes | |||||
| Accrued capital expenditures | |||||
| Dividend equivalent on Series A Preferred Stock | |||||
Loading...